Irish medical device company, Neuromod Devices Ltd, which specializes in the treatment of tinnitus has reached an agreement with Specialklinikken Borgå ApS, a Danish provider of private care for tinnitus, to make its Lenire device available in Denmark. Lenire is “a bimodal neuromodulation device which has shown in clinical trials to reduce the symptoms of tinnitus.” Tinnitus, commonly known as “ringing in the ears”, is a complex neurological condition resulting in the perception of sound without an external source.

Through this distribution agreement, Specialklinikken Borgå’s specialist team has exclusive license from Neuromod to provide Lenire, throughout Denmark, to suitable patients for the treatment of their tinnitus.

“I’m proud that by working with Specialklinikken Borgå we can make Lenire available to people living with tinnitus in Denmark. Tinnitus is globally recognized as a significant healthcare challenge and many people living with the condition have unmet clinical needs. By partnering with tinnitus specialists like Specialklinikken Borgå we’re aiming to improve therapeutic outcomes for these people,” said Dr Ross O’Neill, Founder and CEO of Neuromod Devices.

The agreement comes following Lenire’s launches in Norway and Spain earlier in 2022 and the publication of an independent real-world study demonstrating the safety and efficacy of the Lenire device for improving symptoms in tinnitus patients.

To coincide with the introduction of Lenire to the Danish market, Specialklinikken Borgå ApS is hosting a roadshow of tinnitus seminars throughout Denmark for people living with tinnitus. The roadshow begins in Aarhus with further events in Middlefart, Skive, Odense, Copenhagen, Aalborg, and Esbjerg throughout July and August. Further details about each seminar and tickets are available at:

“I’m delighted that Specialklinikken Borgå are partnering with Neuromod so we can provide an evidence-based treatment option that has seen encouraging patient outcomes in large-scale clinical trials and in the real world. I’m especially looking forward to our roadshow of tinnitus seminars to provide people with tinnitus an opportunity to discuss the breakthrough Lenire treatment,” said Thomas Borgå, Specialklinikken Borgå CEO. 

Lenire is a bimodal neuromodulation device which combines mild electrical pulses to the tongue with sound stimulation to drive neuroplasticity in the brain which reduces the symptoms of tinnitus. It has CE-mark certification for the treatment of tinnitus under the supervision of an appropriately qualified healthcare professional and is currently available throughout Europe.

The device consists of Bluetooth headphones which play customized sounds to activate the auditory nerve, a proprietary intra-oral device which provides mild electrical stimulation to the surface of the tongue, known as a Tonguetip, and a controller which controls the duration and intensity of treatment with the device.

The device’s sound and electrical stimuli can be calibrated to suit a patient’s tinnitus after an initial assessment of their condition which includes an audiological exam. The supervising healthcare professional demonstrates how to use the device and provides the patient with instructions for use. Subsequently, patients use Lenire for 60 minutes per day typically for at least 10 weeks. Follow-up visits with the healthcare professional occur during treatment to monitor patients’ progress.

At the end of the prescribed treatment plan, the healthcare professional advises the patient about their continued use of Lenire.

Source: Lenire

Images: Lenire